ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. This phase 2 double-blind, placebo-controlled,
proof-of-concept, and dose-finding study adaptively randomized patients to receive ABT-089 (5, 10, 15, 20, 30, or 35 mg once daily) or placebo for 12 weeks. The primary efficacy endpoint was the Alzheimer’s Disease Assessment Scale, cognition subscale (ADAS-Cog) total score. A Bayesian
response-adaptive randomization algorithm dynamically assigned allocation probabilities based on interim ADAS-Cog total scores. A normal dynamic linear model for dose-response relationships and a longitudinal model for predicting final ADAS-cog score were employed in the algorithm. Stopping
criteria for futility or success were defined. The futility stopping criterion was met, terminating the study with 337 patients randomized. No dose-response relationship was observed and no dose demonstrated statistically significant improvement over placebo on ADAS-Cog or any secondary endpoint.
ABT-089 was well tolerated at all dose levels. When administered as adjunctive therapy to acetylcholinesterase inhibitors, ABT-089 was not efficacious in mild to moderate Alzheimer disease. The adaptive study design enabled the examination of a broad dose range, enabled rapid determination
of futility, and reduced patient exposure to nonefficacious doses of the investigational compound.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
adaptive trial design;
neuronal nicotinic receptor;
Document Type: Research Article
AbbVie Inc., North Chicago, IL
Berry Consultants, LLC, Austin, TX
Berry Consultants, LLC, Austin, TX, MD Anderson Cancer Center, University of Texas, Houston, TX
Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL, Palm Beach Neurology, West Palm Beach, FL, USA
July 1, 2015